
|Articles|May 25, 2022
The benefits of end-to-end formulation and fill-finish of biologics
Author(s)Curia
The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful. Learn more!
Trending on Pharmaceutical Technology
1
Rasonque's 60% Survival Benefit: What It Means for Oncology Pipelines
2
Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals
3
What to Know from the FDA’s End of August Activity
4
Pharma's Next AI Problem Is Authority
5